Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir kamagra Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

Bolyaisok.ro

Dr. Nicholas Bodor is a Graduate Research Professor Emeritus
(active) at the University of Florida College of Pharmacy,
Gainesville. He joined the university in 1979 as Professor and
Chairman of the Medicinal Chemistry Department, and was

promoted to Graduate Research Professor in 1983. He is the
Executive Director of the college’s Center for Drug Discovery,
founded by him in 1986. During his tenure at the University of
Florida, Dr. Bodor has supervised the training of more than 50
doctoral students and over 100 postdoctoral level research
associates and fellows. In February 2000, he took a leave of
absence from his academic posts at the University of Florida in
order to accept a position as Senior Vice President of Basic
Research and Drug Discovery at the IVAX Corporation. Dr.
Bodor then served as Chief Scientific Officer of the IVAX
Corporation, Managing Director of the IVAX Drug Research
Institute, Budapest, Hungary, as well as President of the IVAX


Research Institute until October 2005.
Dr. Bodor's main research interests include design of drugs with
improved therapeutic index, design of new chemical delivery
systems, computer-assisted drug design, drug transport and
metabolism, and theoretical and mechanistic organic chemistry.
He has published more than 520 research articles, has over 200
patents, and is on the editorial boards of several international
scientific journals. An internationally recognized leader in drug
discovery, design and delivery, he has introduced revolutionary,
general, comprehensive drug design and drug targeting concepts
known as retrometabolic drug design approaches. These concepts
strategically combine chemical and enzymatic (metabolic)
processes to achieve drug targeting and to produce safe drugs
and safe environmental chemicals. The two major classes of the
retrometabolic drug design concepts contain “chemical drug
targeting systems” (CDS) and the “soft drugs” (SD). Each of
these large classes contains various subclasses, based on the
different design rules. The design concepts incorporated in the
soft drug approaches were used by Dr. Bodor to develop a
general and comprehensive program, including a computerized
expert system which can be used to design all potential and
possible metabolites and the corresponding safe active soft drugs
or chemical delivery systems. The soft steroid Loteprednol
Etabonate, designed by Dr. Bodor, is on the market in the U.S.

and other countries. Other drugs designed by him using the
retrometabolic concepts are in advanced clinical development.
The progress in these various related fields is reviewed biennially
at an international series of symposia Dr. Bodor has founded and
organizes entitled, The Retrometabolism Based Drug Design and
Targeting Conference. The ninth meeting of this series is
scheduled for May 2013 in Orlando; in addition to Florida,
venues of the previous eight conferences have included Japan,
Hungary and Austria.

Dr. Bodor received his B.S./M.S. degree in Organic Chemistry in
1959 at Bolyai University in Transylvania, and his Ph.D. degree
in 1965 from the University of Babes-Bolyai, Cluj and the
Romanian National Academy of Sciences. He was a Group
Leader at the Pharmacochemical Research Institute in Romania
until 1968, when he was offered an R. A. Welch Fellowship at the
University of Texas in Austin, where he worked in the field of
theoretical organic chemistry with Dr. Michael J. S. Dewar, the
first Robert A. Welch Research Chair. In 1972 he became a
Senior Research Scientist at ALZA Laboratories in Lawrence,
Kansas, which later became INTERx Research Corporation,
where he was Director of Research, as well as an Adjunct
Professor at the University of Kansas until 1978.

Among his many honors, Dr. Bodor is an elected Fellow of the
Academy of Pharmaceutical Sciences, American Association of
Pharmaceutical Scientists, American Association for the
Advancement of Science, and American College of Clinical
Pharmacology. He is also an Honorary Member of the Hungarian
Chemical Society and the Panhellenic Society of Pharmacists.
Among other honors, Dr. Bodor has been named "The 1984
Florida Scientist of the Year" and received the first AAPS
Research Achievement Award in Medicinal and Natural Product
Chemistry in 1988, as well as the APhA Research Achievement
Award in Pharmaceutical and Medicinal Chemistry in 1989. In
1994 he was named the first recipient of the Nagai Foundation
Tokyo International Fellowship. He was named by the American
Chemical Society as the 1996 recipient of the Leo Friend Award
in recognition of his article entitled, "Design of Biologically Safer
Chemicals," published in Chemtech, October 1995. He is the first
College of Pharmacy faculty member to receive a Professorial
Excellence Award, given by the University of Florida in 1996. The
AACP selected Dr. Bodor as the recipient of the 1997 Volwiler
Research Achievement Award. In April 2000, Dr. Bodor was
named the V. Ravi Chandran Professor in Drug Design and
Targeting of the UF College of Pharmacy, the first recipient of
this endowed professorship. In February 2002, he was elected a
Fellow of the World Innovation Foundation. An honorary Doctor
of Science degree was conferred upon Dr. Bodor by the
University of Florida in 2005. In 2007, the American Association
of Pharmaceutical Scientists awarded Dr. Bodor with the
Distinguished Pharmaceutical Scientist Award.

In addition to the awards above, Dr. Bodor has received the
highest levels of recognition from his home country of Hungary

for his scientific achievements and leadership of the Budapest-
based Institute for Drug Research. In 1989 he received an
honorary Doctor of Science degree from the Technical University
of Budapest, and then was awarded the Doctor Honoris Causa
degree from the Medical University of Debrecen in 1990. In 1995
he was elected to the Hungarian National Academy of Sciences.
Ferenc Madl, President of Hungary, awarded Dr. Bodor the Gold
Cross of Merit of the Hungarian Republic in 2004. In 2010 he
received the prestigious Fabinyi Prize of the Hungarian Chemical
Society, which is given to scientists living outside Hungary whose
outstanding scientific accomplishment have contributed to the
reputation of the HCS. In August 2010 at the national celebration
of Hungary’s over 1000 years statehood and its canonized first
king, St. Stephen, Dr. Bodor was awarded at the Hungarian
Parliament, the Commander’s Cross of the Order of Merit of the
Hungarian Republic, a prestigious award of civil merit.

Dr. Bodor and his wife Sheryl call Miami their primary
residence. He founded Bodor Laboratories, Inc. in 2006, and
works there with his son Erik and daughter Nicole (who hold
PhD/MBA and PhD degrees, respectively, in the relevant fields)
to further develop his drug design strategies to the marketplace.
His oldest son Miklós (an MD, PhD) is Chairman of the Clinical
Pharmacology Department at the Medical University in
Debrecen, Hungary.

In 2012 he was named to the ACS Division of Medicinal
Chemistry Hall of Fame.

Source: http://bolyaisok.ro/wp-content/uploads/2013/10/Bodor-Miklos.pdf

62320-palea735x485

Tadalafil exerts an additive effect on alfuzosin-induced relaxation in pre-contracted human isolated prostatic adenoma Stefano Palea1, Moèz Rekik1, Pascal Rischmann2, Henri Botto3 and Philippe Lluel1 (1) UROsphere, Toulouse, France; (2) CHU Rangueil, Toulouse, France; (3) Foch hospital, Suresnes, FranceThis work was supported by sanofi-aventis INTRODUCTION ● Lower urinary tra

C:\documents and settings\hp_administrator\desktop\roche.profile.wpd

Profile of Hoffmann-LaRoche, Inc. Hoffman-La Roche (Roche) Ltd. was founded in the 1890's, is presently headquartered in Basle,Switzerland on the scenic Rhine, and informs us of its proud tradition. We have been unable todocument a criminal history of Roche prior to 1973, and the era of the late 1990s seems the mostinteresting. In United States v.Hoffman-La Roche Ltd. and Udo Haas , cause num

Copyright © 2010-2014 Internet pdf articles